Previous Close | 46.4 |
1-Year Change | 19.46% |
6-Months Change | 12.95% |
3-Months Change | -17.67% |
Moving Avg (50d) | 53.602 |
Moving Avg (200d) | 48.111 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 3.35B |
Beta (3-Years) | 1.09 |
Revenue Growth (ttm) | 19.46% |
Net Profit Margin (ttm) | -154.87% |
Return On Assets (ttm) | -51.31% |
EPS (ttm) | -8.97 |
PE Ratio (ttm) | -5.17 |
Dividend Yield | % |
Asset Description: | Ultragenyx Pharmaceutical Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-20 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
45.472 | 44.08 | 43.152 | 41.76 | 39.44 | 37.12 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.